Le Lézard
Classified in: Health, Science and technology, Business
Subjects: LIC, JVN

Bluecrux & Pharmaceutical Innovator Forge Path Toward QC & Supply Chain Integration: "Revolutionizing Lab Operations for Enhanced Efficiency"


ORLANDO, Fla., April 18, 2024 /PRNewswire/ -- Bluecrux partnered with global biopharmaceutical leader AstraZeneca to drastically improve lab operations by implementing Binocs, Bluecrux's state of the art lab planning technology, across 17 of AstraZeneca's global quality control laboratories. This strategic collaboration tackles the industry-wide challenge of seamlessly integrating quality control (QC) into supply chain (SC) operations to enhance operational efficiency and responsiveness. Bluecrux and AstraZeneca will delve into the fruits of their productive partnership on stage at the Gartner Supply Chain Symposium/Xpo in Orlando, Florida, May 6 to 8.

Like many biopharmaceutical companies, AstraZeneca saw a significant opportunity for integration between quality control and their supply chain. When quality control labs?critical in ensuring the safety and efficacy of pharmaceutical products?operate in isolation from the supply chain, a longer response time is required to meet fluctuating demands and ultimately patient needs. On top, connecting QC and supply chain will result in direct and positive impact on  lead times, inventory costs and regulatory compliance.

Enter Bluecrux's technology Binocs, which integrates QC into the heart of supply chain operations, enabling precise capacity management and forecasting. By forecasting production needs and aligning them with QC capabilities, Binocs ensures that equipment and staff are optimally deployed, dramatically improving capacity utilization and accelerating product release cycles.

The partnership between Bluecrux and AstraZeneca is more than a digital transformation project; it's a fusion of shared values aimed at charting a future in which supply chain and quality control are fully integrated. This collaboration promises to unlock significant hidden value, reducing lead times and inventory costs, consequently boosting AstraZeneca's agility and competitiveness in the global market which allows them to accelerate their delivery of medicines to patients around the globe.

"Through this collaboration, AstraZeneca has not only created deep and rich insights into their local and global network laboratory capacity, but they are transforming the culture and effectiveness of their planning processes by enabling collaborative and impactful discussions between QC and Supply Chain." Says Scott Barnard, Managing Director Bluecrux US.

You can learn more about Bluecrux and AstraZeneca's QC and supply chain integration project in Orlando in May (6 May, 4PM EDT), where Gartner will facilitate both partners to discuss their collaboration in greater depth on stage. Registrations to the Gartner Supply Chain Symposium event are via the Gartner organization. Gartner is closely following up on this topic, which is at the forefront of supply chain innovation in the pharmaceutical industry.

About Bluecrux

Founded in 2011, Bluecrux is a leading value chain technology and consulting company, providing solutions at "the Cutting X". Bluecrux experts and software help to transform today's supply chains into smart, efficient, and fully integrated value chains. Bluecrux offers solutions that fit the unique complexities of businesses in life sciences, consumer goods, chemicals and industrial manufacturing. This for the world's largest companies, including Johnson & Johnson, GSK, Roche, Bridgestone, AkzoNobel, Beiersdorf, Legend Biotech, and many more. Our desire to work closely with them is also?reflected?in our global presence, with offices both in Europe and the US. 

To discover more, please visit?www.bluecrux.com?? 

SOURCE Bluecrux


These press releases may also interest you

at 17:30
Tuya Inc. ("Tuya" or the "Company") , a global leading cloud platform service provider, today announced its unaudited financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Total revenue was US61.7...

at 17:00
Zepp Health Corporation ("Zepp" or the "Company") today reported revenues of US$39.8 million; a basic and diluted net loss per share of US$0.06; and a basic and diluted net loss per ADS of US$0.23 for the first quarter ended March 31, 2024;...

at 17:00
Yalla Group Limited ("Yalla" or the "Company") , the largest Middle East and North Africa (MENA)-based online social networking and gaming company, today announced its unaudited financial results for the first quarter ended March 31, 2024. First...

at 16:56
A paper published in the June edition of the Journal Diabetes demonstrates that C-peptide, a biomarker that indicates the production of insulin, is a validated surrogate endpoint, or predictor of clinical benefit, for clinical trials of...

at 16:42
Karman Space & Defense ("Karman"), a concept-to-production solutions provider for the most complex challenges in our industry, proudly announces the launch of its captivating, newly redesigned website, and bold tagline "Impossible Ends Here."...

at 16:35
Nordson Corporation today reported results for the fiscal second quarter ended April 30, 2024. Sales were $651 million, comparable to the prior year's second quarter sales of $650 million. The second quarter 2024 sales included a favorable...



News published on and distributed by: